425: Quanterix to Acquire Akoya Biosciences in Stock-Based Merger

Quanterix is set to acquire Akoya Biosciences in a stock-for-stock transaction aimed at creating a leader in biomarker detection across blood and tissue.

Summary

• Quanterix Corporation has entered into a definitive agreement to acquire Akoya Biosciences.
• Akoya shareholders will receive 0.318 shares of Quanterix stock for each Akoya share, resulting in a pro forma ownership of 70% for Quanterix shareholders and 30% for Akoya shareholders.
• The merger is expected to close in the second quarter of 2025, pending shareholder and regulatory approvals.
• The combined company aims to create a comprehensive suite of technology offerings in neurology, oncology, and immunology.
• The merger is projected to yield $40 million in synergies by the end of 2026, with $20 million expected within the first year.
• The combined company had approximately $220 million in revenues based on the trailing 12-month period ended September 30, 2024.
• The combined cash balance is expected to be approximately $175 million at closing, after accounting for debt repayment, transaction costs, and the EMISSION acquisition payment.
• Quanterix expects the merger to accelerate its path to profitability, targeting cash flow positivity in 2026.
• Vandana Sriram and Masoud Toloue will continue to lead Quanterix, and two Akoya directors will join the Quanterix Board of Directors.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook on the merger, highlighting the strategic fit, potential synergies, and growth opportunities for the combined company. Management's comments and the overall tone suggest confidence in the success of the transaction.

Positives

• The merger creates a leader in biomarker detection with a comprehensive suite of technology offerings.
• The combined company will target high-growth markets in neurology, oncology, and immunology.
• The merger is expected to generate $40 million in synergies by the end of 2026.
• The combined company is expected to have a strong cash balance of $175 million at closing.
• Quanterix expects the merger to accelerate its path to profitability, targeting cash flow positivity in 2026.
• The merger expands Quanterix's reach into adjacencies, particularly in oncology and immunology.
• The combined company will have a larger installed base of over 2,300 instruments, creating cross-selling opportunities.
• The merger supports Quanterix's strategic plan to grow its menu, expand into adjacencies, and translate into Alzheimer's disease diagnostics.

Negatives

• The merger is subject to shareholder and regulatory approvals, which could delay or prevent the transaction from closing.
• Integrating the two companies could be challenging and may not result in the anticipated synergies.
• The merger could divert management's attention from ongoing business operations and opportunities.
• There are potential risks related to the dilutive effect of Quanterix common stock to be issued in the merger.

Risks

• The occurrence of any event that could give rise to the termination of the merger agreement.
• The outcome of any legal proceedings that may be instituted against Quanterix or Akoya.
• Failure to obtain necessary regulatory and stockholder approvals.
• The anticipated benefits and synergies of the merger may not be realized.
• The merger may be more expensive to complete than anticipated.
• Potential adverse reactions or changes to business or employee relationships.
• Changes in Quanterix's share price before the closing of the merger.
• Risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the merger.

Future Outlook

The combined company expects to achieve strong double-digit organic revenue growth and accelerate its path to profitability, targeting cash flow positivity in 2026.

Management Comments

• Masoud Toloue, President and CEO of Quanterix, believes the transaction is a strong fit with their strategy and will create a true leader in the space.
• Masoud Toloue stated that the combined company will have a one-of-a-kind integrated platform across the detection of blood and tissue-based protein biomarkers.
• Vandana Sriram, Chief Financial Officer of Quanterix, echoed excitement for the future of the combined company and its accelerated path to profitability.
• Masoud Toloue mentioned the importance of expanding into adjacencies like oncology and immunology to enhance their offerings.
• Vandana Sriram highlighted the opportunity to leverage a common operating and commercial infrastructure to realize considerable synergies.

Industry Context

The merger reflects a trend towards consolidation in the life science tools industry, with companies seeking to offer more comprehensive solutions to researchers and clinicians. The combination of Quanterix's expertise in blood-based biomarker detection with Akoya's spatial biology capabilities positions the combined entity to compete more effectively in the growing markets of neurology, oncology, and immunology.

Comparison to Industry Standards

• Quanterix's Simoa platform competes with technologies from companies like Luminex and Meso Scale Discovery (MSD) in the biomarker detection space.
• Akoya Biosciences competes with companies like NanoString Technologies and 10x Genomics in the spatial biology market.
• The combined company aims to offer a more integrated solution than competitors by combining blood-based and tissue-based biomarker analysis.
• The $40 million in expected synergies is a typical target for mergers of this size in the life science tools industry.
• The combined cash balance of $175 million will provide the company with resources to invest in R&D and commercial expansion, similar to other players in the industry.

Management Changes

Stakeholder Impact

• Shareholders of both Quanterix and Akoya will be impacted by the merger, with Akoya shareholders receiving Quanterix stock.
• Employees of both companies may experience changes in their roles and responsibilities as the organizations integrate.
• Customers of both companies are expected to benefit from a more comprehensive suite of technology offerings.
• Vendors of both companies may be impacted by the consolidation of operations and supply chains.

Next Steps

• Quanterix and Akoya will file a registration statement on Form S-4 with the SEC.
• The companies will seek shareholder and regulatory approvals for the merger.
• A joint cross-functional integration planning team will be formed.
• The integration team will develop plans for combining the businesses.
• The merger is expected to close in the second quarter of 2025.
• The combined company will focus on integrating the two organizations and realizing synergies.

Key Dates